Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.81 |
| ▸ | PPARA | Q07869 | 3/20 | 0.81 |
| ▸ | CNR2 | P34972 | 11/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838949 | 1.00 | CNR1 (0.81) | CNR1PPARACNR2 | |
| SCHEMBL29838948 | 0.90 | CNR1 (0.79) | CNR1PPARACNR2 | |
| SCHEMBL29838934 | 0.89 | CNR1 (0.79) | CNR1PPARACNR2 | |
| SCHEMBL29838890 | 0.89 | CNR1 (0.73) | CNR1PPARACNR2 | |
| SCHEMBL29838997 | 0.89 | CNR2 (0.73) | CNR1PPARACNR2 | |
| SCHEMBL29838931 | 0.88 | CNR1 (0.75) | CNR1PPARACNR2 | |
| SCHEMBL29838933 | 0.88 | CNR2 (0.69) | CNR1PPARACNR2 | |
| SCHEMBL4877355 | 0.87 | CNR1 (0.77) | CNR1PPARACNR2 | |
| SCHEMBL29838945 | 0.87 | CNR2 (0.67) | CNR1PPARACNR2 | |
| SCHEMBL29838939 | 0.87 | CNR2 (0.68) | CNR1PPARACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683672-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Beone Medicines I GmbH (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-20260007761-A1 | Bioactive Conjugate, Preparation Method Therefor and Use Thereof | BEONE MEDICINES I GMBH (CH) | 2026-01-08 | — | — | US | disclosed |
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2025-09-25 | — | — | US | disclosed |
| EP-4594327-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BeiGene Switzerland GmbH (CH) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025032556-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024194851-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024067811-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE, LTD. (KY) | 2024-04-04 | — | — | WO | disclosed |
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2022164239-A1 | PYRAZOLE-CARBOXAMIDE DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 파미노젠 | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007761-A1 | Bioactive Conjugate, Preparation Method Therefor and Use Thereof | IGLV6-57, BCR, INCENP | CNR1 3201/4885PPARA 3974/4885CNR2 3441/4885 |
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | SLC10A1, ERBB3, SLC10A2 | CNR1 464/4885PPARA 322/4885CNR2 544/4885 |
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | SDCBP, TEK, TEKT1 | CNR1 4854/4885PPARA 4775/4885CNR2 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.